Story has been updated to add attorney comment.
Last week, the U.S. Food and Drug Administration asked Endo Pharmaceuticals Inc. of Newark, New Jersey, to remove Opana ER, its extended-release version of oxymorphone hydrochloride, from the market after the agency found a likelihood of abuse by crushing up and injecting the pills. According to the FDA, it is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the risks of abuse.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
